Abstract
We thank Siddharth Jain and colleagues for their interest in our Article;1 they underline that in the Tocilizumab in Patients with Severe COVID-19 Pneumonia (TESEO) cohort, there was no difference in efficacy of the subcutaneous tocilizumab formulation compared with the intravenous route, and they advocate for use of the subcutaneous formulation due to an approximately six-times cost reduction. However, we argue that intravenous administration has other advantages—eg, a pharmacokinetic profile that is more linear and predictable compared with the subcutaneous formulation, for which proteolytic degradation can be variable.
Highlights
Therapeutic efficacy in severe COVID-19 pneumonia seems incomplete without a discussion of the chest radiology
We thank Siddharth Jain and col leagues for their interest in our Article;[1] they underline that in the Tocilizumab in Patients with Severe COVID-19 Pneumonia (TESEO) cohort, there was no difference in efficacy of the subcutaneous tocilizumab formulation compared with the intra venous route, and they advocate for use of the subcutaneous formulation due to an approximately six-times cost reduction
We agree that determining the optimal time for tocilizumab adminis tration in patients with COVID-19 is crucial
Summary
We thank Siddharth Jain and col leagues for their interest in our Article;[1] they underline that in the Tocilizumab in Patients with Severe COVID-19 Pneumonia (TESEO) cohort, there was no difference in efficacy of the subcutaneous tocilizumab formulation compared with the intra venous route, and they advocate for use of the subcutaneous formulation due to an approximately six-times cost reduction. A potential divergence in these two groups, if identified, could go a long way in optimising the current use of tocilizumab in COVID-19.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
